Loading
companiesCompany
Lyvgen Biopharma
Lyvgen Biopharma is a Shanghai antibody company that builds agonists of immune-activating receptors such as CD137 and CD40; its CD137 antibody LVGN6051 is being tested with PD-1 blockade.
Also called: Lyvgen Biopharma Holdings礼进生物
Overview
Lyvgen Biopharma develops next-generation immuno-oncology antibodies with engineered Fc regions that tune their crosslinking and activity. LVGN6051 is a CD137 (4-1BB) agonist designed to activate T cells within tumours while limiting the liver toxicity seen with earlier agents; it is in phase 1 trials alone and with pembrolizumab or anlotinib. LVGN7409 is a CD40 agonist and LVGN3616 is a PD-1 antibody.
Headquarters
Shanghai, CN
Scorecard
All companies#465of 1244 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Monoclonal antibody
LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma.
drugs
Phase 2Monoclonal antibody